TP53 and cancer: Hinokiflavone was identified using structure-based virtual screening as a candidate compound that showed activity to bind the MDM2-MDMX RING dimer, inhibit the MDM2-mediated ubiquitination, and exhibited p53-dependent and independent anti-cancer effects.